NEW YORK, March 29, 2024 (GLOBE NEWSWIRE) — Bernstein Liebhard LLP:
- Do you, or did you, own shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV)?
- Did you purchase your shares between June 28, 2021 and March 13, 2024, inclusive?
- Did you lose money in your investment in Evolv Technologies Holdings, Inc.?
- Do you want to discuss your rights?
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp. (“Evolv” or the “Company”) (NASDAQ: EVLV) between June 28, 2021 and March 13, 2024, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the District of Massachusetts and alleges violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you purchased or acquired Evolv securities, and/or would like to discuss your legal rights and options please visit Evolv Technologies Holdings, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
If you wish to serve as lead plaintiff, you must move the Court no later than May 24, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
According to the Complaint, Defendants failed to disclose to investors that: (1) Evolv materially overstated the efficacy of its products; (2) the lack of effectiveness of Evolv’s products with regard to detecting knives and guns led to an increased risk of undetected weapons entering locations such as schools; and (3) Evolv deceived the general public, its customers, and its investors regarding the effectiveness of its products.
On February 20, 2024, before the market opened, Evolv stated in a Form 8-K filed with the SEC that “on Friday, February 16, 2024 the SEC notified the Company it was initiating an investigation that was described as a confidential ‘non-public, fact finding inquiry.’” On this news, which is alleged to be related to the Evolv’s technology, the price of Evolv stock fell by $0.82 per share, or 15.67%, to close at $4.41 on February 20, 2024.
On March 13, 2024, the BBC released an article entitled “AI weapons scanner backtracks on UK testing claims” (the “Article”). Among other things, the Article stated that “[t]he company had said that its AI weapons scanner had been tested by the UK Government’s National Protective Security Authority (NPSA)[.] . . . On 20 February the company put out a press release, including a claim that the NPSA was one of a number of testers who had ‘concluded that the Evolv Express solution was highly effective at detecting firearms and many other types of weapons’. But BBC News can reveal the NPSA does not do this type of testing.”
On this news, Evolv’s stock price declined by $0.13 per share, or over 3%, to close at $3.57 per share on March 13, 2024.
If you purchased or acquired Evolv securities, and/or would like to discuss your legal rights and options please visit Evolv Technologies Holdings, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2024 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
https://www.bernlieb.com
(212) 951-2030
pallocco@bernlieb.com
- Suominen has signed a credit facility agreement - July 3, 2025
- THEON receives a new order from a Northern European country for the thermal clip-on IRIS -C and swiftly converts soft backlog to hard backlog - July 3, 2025
- Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies - July 3, 2025
